Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) traded down 2.1% during mid-day trading on Friday . The stock traded as low as $13.57 and last traded at $14.65, with a volume of 52,855 shares traded. The stock had previously closed at $14.97.

Several equities research analysts have recently issued reports on the company. Credit Suisse Group AG assumed coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They issued an “outperform” rating and a $25.00 target price on the stock. Cowen and Company assumed coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They issued an “outperform” rating on the stock. Guggenheim assumed coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They issued a “buy” rating and a $24.00 target price on the stock. Cantor Fitzgerald assumed coverage on Corvus Pharmaceuticals in a report on Monday, April 18th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, BTIG Research assumed coverage on Corvus Pharmaceuticals in a report on Tuesday, April 19th. They issued a “buy” rating and a $22.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $21.60.

The company has a 50-day moving average of $13.68 and a 200-day moving average of $13.64. The company’s market capitalization is $298.95 million.

In other news, major shareholder A/S Novo bought 70,000 shares of the stock in a transaction dated Thursday, May 12th. The shares were acquired at an average cost of $10.00 per share, with a total value of $700,000.00. Following the purchase, the insider now directly owns 3,224,046 shares in the company, valued at approximately $32,240,460. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Orbimed Advisors Llc bought 38,383 shares of the stock in a transaction dated Tuesday, June 21st. The shares were purchased at an average cost of $12.75 per share, for a total transaction of $489,383.25. The disclosure for this purchase can be found here.

Corvus Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.